59
Participants
Start Date
May 17, 2022
Primary Completion Date
November 17, 2026
Study Completion Date
November 17, 2027
Spartalizumab in Pediatric cohort
Infusion of spartalizumab at four dose escalation levels: 2, 3, 4 and 6 mg/kg in successive cohorts of 3 patients, depending on the number of patients with dose-limiting toxicity (DLT) to maximum tolerated dose (MTD).
Low-dose Pazopanib in Pediatric Cohort
Oral pazopanib treatment at a fixed dose of 225mg/m²/day
Spartalizumab in Adult cohort
Infusion of 400 mg of spartalizumab on Day1 of each cycle.
Low-dose Pazopanib in Adult Cohort
Oral pazopanib treatment with a fixed dose of 400 mg/day
RECRUITING
APHM Hôpital des Enfants La Timone - Hématologie Oncologie Pédiatrique, Marseille
RECRUITING
CHU de Bordeaux - Unité d'Hématologie et d'Oncologie pédiatrique, Bordeaux
RECRUITING
Institut Bergonié - Oncologie Médicale, Bordeaux
RECRUITING
Centre Oscar Lambret - Oncologie pédiatrie, Lille
RECRUITING
Centre Léon Bérard - Oncologie Médicale, Lyon
RECRUITING
Institut d'Hématologie et d'Oncologie Pédiatrique (IHOP) - Oncologie pédiatrique, Lyon
RECRUITING
Institut Curie - Centre D'Oncologie SIREDO, Paris
RECRUITING
Gustave Roussy - Oncologie pédiatrique, Villejuif
RECRUITING
CHU d'Angers - Unité d'Hématologie et d'Oncologie pédiatrique, Angers
Collaborators (1)
National Cancer Institute, France
OTHER_GOV
Fondation ARC
OTHER
Novartis
INDUSTRY
University Hospital, Bordeaux
OTHER